Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager

Sebastian Gallo-Bernal, Nasly Patino-Jaramillo, Camilo A. Calixto, Sergio A. Higuera, Julian F. Forero, Juliano Lara Fernandes, Carlos Góngora, Michael S. Gee, Brian Ghoshhajra, Hector M. Medina

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Gadolinium-enhanced cardiac magnetic resonance has revolutionized cardiac imaging in the last two decades and has emerged as an essential and powerful tool for the characterization and treatment guidance of a wide range of cardiovascular diseases. However, due to the high prevalence of chronic renal dysfunction in patients with cardiovascular conditions, the risk of nephrogenic systemic fibrosis (NSF) after gadolinium exposure has been a permanent concern. Even though the newer macrocyclic agents have proven to be much safer in patients with chronic kidney disease and end-stage renal failure, clinicians must fully understand the clinical characteristics and risk factors of this devastating pathology and maintain a high degree of suspicion to prevent and recognize it. This review aimed to summarize the existing evidence regarding the physiopathology, clinical manifestations, diagnosis, and prevention of NSF related to the use of gadolinium-based contrast agents.

Original languageEnglish (US)
Article number1816
JournalDiagnostics
Volume12
Issue number8
DOIs
StatePublished - Aug 2022
Externally publishedYes

Keywords

  • cardiac magnetic resonance
  • chronic kidney disease
  • gadolinium-based contrast agents
  • nephrogenic systemic fibrosis

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Nephrogenic Systemic Fibrosis in Patients with Chronic Kidney Disease after the Use of Gadolinium-Based Contrast Agents: A Review for the Cardiovascular Imager'. Together they form a unique fingerprint.

Cite this